- Zydus Lifesciences has reported a net income of 11.8 billion rupees in 4Q, surpassing previous estimates of 10.36 billion rupees.
- The company’s net income has seen a significant increase from the previous year’s 2.97 billion rupees.
- Revenue for 4Q stands at 55.3 billion rupees, which is a growth of 10% year-on-year. The estimated revenue was 53.8 billion rupees.
- The total costs have also increased by 4.5% from the previous year, reaching 41.4 billion rupees. The estimated costs were lower, at 38.43 billion rupees.
- Other income has also seen a substantial increase from the previous year, standing at 1.56 billion rupees as compared to 378 million rupees.
- In response to this positive financial performance, the company’s shares have risen by 4.2%, reaching 1,051 rupees. The rise is based on the trading of 3.02 million shares.
- In terms of investment ratings, there are currently 17 buys, 10 holds, and 6 sells on the company’s shares.
- The reported results are based on values provided by the company’s original disclosures.
Zydus Lifesciences Ltd on Smartkarma
On Smartkarma, investment analyst Tina Banerjee provides coverage on Zydus Lifesciences Ltd, highlighting the company’s strong performance in Q3FY24. Zydus Lifesciences reported a notable 27% increase in net profit, driven by robust revenue growth and improved profitability. Moreover, the company approved a significant buyback of INR 6 billion, signaling confidence in its outlook.
This bullish sentiment is supported by Zydus Lifesciences’ 16% YoY and 7% QoQ growth in India formulation business revenue during Q3FY24. The company’s focus on healthy volume growth and new product launches has led to continued profitability enhancement, with a 200 basis points YoY improvement to 24.5% in Q3FY24. The approved buyback, representing 0.59% of total outstanding equity shares, at a premium price of INR 1005 per share, further underscores the positive outlook for Zydus Lifesciences Ltd.
A look at Zydus Lifesciences Ltd Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 4 | |
| Growth | 3 | |
| Resilience | 4 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 3.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Analysts using Smartkarma Smart Scores have provided insight into the long-term outlook for Zydus Lifesciences Ltd. With impressive scores in areas such as Dividend and Momentum, the company is positioned favorably for the future. The firm’s resilience score also bolsters confidence in its ability to weather market fluctuations. Although not scoring as high in Value and Growth, Zydus Lifesciences Ltd still maintains a competitive standing, showcasing a promising outlook.
Zydus Lifesciences Ltd, a subsidiary of Cadila Healthcare Ltd, operates in the healthcare sector with a diverse product portfolio. Offering a wide range of healthcare solutions, from active pharmaceutical ingredients to animal healthcare products, the company caters to various market segments. Their array of products in different forms reflects their commitment to meeting consumer needs efficiently.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
